undamentalytics Newsletter
Sign in

C4 Therapeutics, Inc. balance sheet

At the end of fiscal 2025, C4 Therapeutics, Inc. had total assets of $359m, total liabilities of $102m and shareholders' equity of $257m. It held $74.6m in cash against $0 of debt: net cash of $74.6m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents7630127557579
Receivables6112321
Total current assets326288271258258263
Total assets507431376350359359
Accounts payable511111
Deferred revenue (current)321715191227
Total current liabilities514543453348
Short-term debt020———
Long-term debt1190———
Total debt13130000
Total liabilities117142130134102112
Shareholders' equity390289246216257247
Net debt (negative = net cash)−64−17−127−55−75−79
Shares outstanding49m49m60m71m97m123m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: BHST vs CCCCCCCC vs VYGRCCCC vs FHTX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from C4 Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to C4 Therapeutics, Inc.